1053 related articles for article (PubMed ID: 21146655)
1. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.
Mauri L; Kereiakes DJ; Normand SL; Wiviott SD; Cohen DJ; Holmes DR; Bangalore S; Cutlip DE; Pencina M; Massaro JM
Am Heart J; 2010 Dec; 160(6):1035-41, 1041.e1. PubMed ID: 21146655
[TBL] [Abstract][Full Text] [Related]
2. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.
Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
JAMA; 2015 Mar; 313(11):1113-21. PubMed ID: 25781440
[TBL] [Abstract][Full Text] [Related]
4. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery stenosis-Extended Antiplatelet Monotherapy (HOST-EXAM) trial.
Lee H; Koo BK; Park KW; Shin ES; Lim SW; Rha SW; Bae JW; Jeon DW; Oh SK; Hur SH; Kim BS; Lee JH; Park TH; Lee NH; Kim HS;
Am Heart J; 2017 Mar; 185():17-25. PubMed ID: 28267471
[TBL] [Abstract][Full Text] [Related]
6. Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial.
Yang H; Zhang F; Yang J; Zheng M; Cao R; Dai Y; Li C; Yao K; Qian J; Ge J;
BMJ Open; 2019 Dec; 9(12):e033774. PubMed ID: 31852711
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study.
Byrne RA; Schulz S; Mehilli J; Iijima R; Massberg S; Neumann FJ; ten Berg JM; Schömig A; Kastrati A;
Am Heart J; 2009 Apr; 157(4):620-4.e2. PubMed ID: 19332187
[TBL] [Abstract][Full Text] [Related]
8. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.
Yeh RW; Kereiakes DJ; Steg PG; Windecker S; Rinaldi MJ; Gershlick AH; Cutlip DE; Cohen DJ; Tanguay JF; Jacobs A; Wiviott SD; Massaro JM; Iancu AC; Mauri L;
J Am Coll Cardiol; 2015 May; 65(20):2211-21. PubMed ID: 25787199
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Helft G; Le Feuvre C; Georges JL; Carrie D; Leclercq F; Eltchaninoff H; Furber A; Prunier F; Sebagh L; Cattan S; Cayla G; Vicaut E; Metzger JP
Trials; 2013 Feb; 14():56. PubMed ID: 23433461
[TBL] [Abstract][Full Text] [Related]
10. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement.
Garratt KN; Weaver WD; Jenkins RG; Pow TK; Mauri L; Kereiakes DJ; Winters KJ; Christen T; Allocco DJ; Lee DP
Circulation; 2015 Jan; 131(1):62-73. PubMed ID: 25400062
[TBL] [Abstract][Full Text] [Related]
11. Five-year results of the Multicenter Randomized Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients.
Sinning JM; Baumgart D; Werner N; Klauss V; Baer FM; Hartmann F; Drexler H; Motz W; Klues H; Voelker W; Pfannebecker T; Stoll HP; Nickenig G;
Am Heart J; 2012 Mar; 163(3):446-53, 453.e1. PubMed ID: 22424016
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
13. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
[TBL] [Abstract][Full Text] [Related]
14. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
Hermiller JB; Krucoff MW; Kereiakes DJ; Windecker S; Steg PG; Yeh RW; Cohen DJ; Cutlip DE; Massaro JM; Hsieh WH; Mauri L;
JACC Cardiovasc Interv; 2016 Jan; 9(2):138-47. PubMed ID: 26793956
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
Kedhi E; Fabris E; van der Ent M; Kennedy MW; Buszman P; von Birgelen C; Cook S; Wedel H; Zijlstra F
Am Heart J; 2017 Jun; 188():11-17. PubMed ID: 28577666
[TBL] [Abstract][Full Text] [Related]
16. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
Kim BK; Hong MK; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Kang TS; Park BE; Kang WC; Lee SH; Yoon JH; Hong BK; Kwon HM; Jang Y;
J Am Coll Cardiol; 2012 Oct; 60(15):1340-8. PubMed ID: 22999717
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy.
Urban P; Abizaid A; Chevalier B; Greene S; Meredith I; Morice MC; Pocock S
Am Heart J; 2013 May; 165(5):704-9. PubMed ID: 23622906
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.
Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Park SJ; Lee JH; Choi SW; Seong IW; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Choi YJ; Kim HS; Lee BK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Park WJ;
J Am Coll Cardiol; 2011 Mar; 57(11):1264-70. PubMed ID: 21392640
[TBL] [Abstract][Full Text] [Related]
19. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.
Colombo A; Chieffo A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Oteo Dominguez JF; Steffanon L; Tarantini G; Presbitero P; Menozzi A; Pucci E; Mauri J; Cesana BM; Giustino G; Sardella G
J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2086-97. PubMed ID: 25236346
[TBL] [Abstract][Full Text] [Related]
20. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Mauri L; Kereiakes DJ; Yeh RW; Driscoll-Shempp P; Cutlip DE; Steg PG; Normand SL; Braunwald E; Wiviott SD; Cohen DJ; Holmes DR; Krucoff MW; Hermiller J; Dauerman HL; Simon DI; Kandzari DE; Garratt KN; Lee DP; Pow TK; Ver Lee P; Rinaldi MJ; Massaro JM;
N Engl J Med; 2014 Dec; 371(23):2155-66. PubMed ID: 25399658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
